SunTrust analyst Bruce Nudell raised his price target on Zimmer Biomet to $135 and kept his Buy rating after its Q4 results and FY19 guidance, saying the quarter also showed improving supply issues and abating FDA worries. The analyst further expects the company’s new products to improve its outlook, with the “flagship” knee franchise set to “rebound with the full launch of the Persona revision,cement-less and partial offerings as well as the introduction of the ROSA robotic solution.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.